Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Verona pharma plc crawled time : 08:00 save search
Verona Pharma to Report First Quarter 2023 Financial Results and Provide Corporate Update
Published: 2023-04-25 (Crawled : 08:00) - biospace.com/
VRNA | $15.21 -2.44% -2.5% 320K
|
Health Technology
|
| O: -0.7%
H: 2.41%
C: -1.07%
pharma report update financial results
Verona Pharma Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
Published: 2023-03-07 (Crawled : 08:00) - globenewswire.com
VRNA | $15.21 -2.44% -2.5% 320K
|
Health Technology
|
| O: -4.19%
H: 1.32%
C: -6.6%
pharma year financial update results
Verona Pharma Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Published: 2022-11-09 (Crawled : 08:00) - globenewswire.com
VRNA | $15.21 -2.44% -2.5% 320K
|
Health Technology
|
| O: 0.54%
H: 3.31%
C: -5.0%
pharma financial update results
Verona Pharma Secures Debt Financing of up to $150 Million from Oxford Finance
Published: 2022-10-17 (Crawled : 08:00) - biospace.com/
VRNA | $15.21 -2.44% -2.5% 320K
|
Health Technology
|
| O: 2.1%
H: 2.74%
C: 1.17%
pharma
Polypeptide Therapeutic Solutions (PTS) Announces Company Name Change to Curapath and Expansion of Drug Delivery Capabilities and Services Polypeptide Therapeutic Solutions, a leader in the design, dev...
Published: 2022-10-17 (Crawled : 08:00) - biospace.com/
VRNA | $15.21 -2.44% -2.5% 320K
|
Health Technology
|
| O: 2.1%
H: 2.74%
C: 1.17%
GLPG | News | $28.78 -2.28% -2.33% 140K
|
Health Technology
|
| O: 2.32%
H: 0.92%
C: 0.22%
ALKS | $24.66 1.65% 1.62% 1.7M
|
Health Technology
|
| O: 0.4%
H: 2.42%
C: 1.81%
expansion drug solutions services change
Verona Pharma Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Published: 2022-08-09 (Crawled : 08:00) - globenewswire.com
VRNA | $15.21 -2.44% -2.5% 320K
|
Health Technology
|
| O: 101.29%
H: 5.0%
C: -28.31%
pharma update results
Verona Pharma to Present Successful TQT Analysis Demonstrating No Clinically Relevant Effect on Cardiac Conduction at the American Thoracic Society 2022
Published: 2022-05-09 (Crawled : 08:00) - biospace.com/
VRNA | $15.21 -2.44% -2.5% 320K
|
Health Technology
|
| O: -2.28%
H: 0.0%
C: -8.03%
pharma cardiac
Verona Pharma Announces May 2022 Investor Conference Participation
Published: 2022-05-04 (Crawled : 08:00) - biospace.com/
VRNA | $15.21 -2.44% -2.5% 320K
|
Health Technology
|
| O: 0.0%
H: 9.54%
C: -0.98%
pharma conference
Verona Pharma Reports First Quarter 2022 Financial Results and Provides Corporate Update
Published: 2022-05-03 (Crawled : 08:00) - biospace.com/
VRNA | $15.21 -2.44% -2.5% 320K
|
Health Technology
|
| O: -2.62%
H: 0.0%
C: 0.0%
pharma results
Verona Pharma Reports TQT Study Successfully Demonstrated No Clinically Relevant Effect on Cardiac Conduction
Published: 2021-12-16 (Crawled : 08:00) - globenewswire.com
VRNA | $15.21 -2.44% -2.5% 320K
|
Health Technology
|
| O: 0.87%
H: 11.26%
C: 9.74%
cardiac pharma
Verona Pharma Reports Third Quarter 2021 Financial Results and Provides Corporate Update
Published: 2021-11-09 (Crawled : 08:00) - globenewswire.com
VRNA | $15.21 -2.44% -2.5% 320K
|
Health Technology
|
| O: 3.08%
H: 0.0%
C: 0.0%
financial results results pharma
Verona Pharma Announces November 2021 Investor Conference Participation
Published: 2021-11-01 (Crawled : 08:00) - globenewswire.com
VRNA | $15.21 -2.44% -2.5% 320K
|
Health Technology
|
| O: -0.2%
H: 4.5%
C: 3.33%
conference pharma
Verona Pharma to Present at Jefferies Virtual Healthcare Conference - May 25, 2021
Published: 2021-05-25 (Crawled : 08:00) - biospace.com/
VRNA | $15.21 -2.44% -2.5% 320K
|
Health Technology
|
| O: 0.69%
H: 6.14%
C: -2.39%
conference pharma
Verona Pharma Reports First Quarter 2021 Financial Results and Provides Corporate Update
Published: 2021-04-29 (Crawled : 08:00) - biospace.com/
VRNA | $15.21 -2.44% -2.5% 320K
|
Health Technology
|
| O: 1.81%
H: 3.39%
C: -7.23%
financial results results pharma
Verona Pharma Completes Enrollment in Pilot Study of pMDI Ensifentrine in U.S. Patients Hospitalized with COVID-19Top-line results expected in 2Q 2021
Published: 2021-01-14 (Crawled : 08:00) - biospace.com/
VRNA | $15.21 -2.44% -2.5% 320K
|
Health Technology
|
| O: 1.37%
H: 6.14%
C: 3.23%
covid results enroll
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.